ALFA Finder| Execution period | 60 months |
|---|
NSE filing, NSE: CONCORDBIO. Summary written from the filing by ALFA Finder's alert engine.
Concord Biotech Ltd: key numbers
- Share price
- ₹597.20
- Market cap
- ₹12,495 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 44.2×Sector 43.8×
- Promoter holding
- 44.09%+0.01% QoQ
- FII holding
- 7.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Bonus Issue
Concord Biotech allotted 10,46,16,204 bonus shares in a 1:1 ratio. Total equity shares rise to 20,92,32,408 after the bonus allotment.
Concord Biotech Earnings Call Transcript: Key Takeaways
Revenue grew 25% YoY driven by API demand, but gross margins contracted 400bps due to rising solvent costs and geopolitical disruptions.
- Call
- Guides 18% growth
Concord Biotech Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹309.1 Cr (+25%) and PAT ₹69.6 Cr (+10%); H1 revenue ₹566.6 Cr (+26%). Margins compressed; Inspira dermatology division launched.
Concord Biotech Bonus Issue
Concord Biotech fixed 4 November 2026 as the record date for a 1:1 bonus issue, with deemed allotment on 5 November 2026. The bonus is subject to statutory and regulatory approvals.
Concord Biotech Q2 FY27 Results: Net Profit ₹69.6 Cr, Up 10.3% YoY
Concord Biotech Ltd reported revenue from operations of ₹309.1 Cr (+25.1% YoY) and net profit of ₹69.6 Cr (+10.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹69.6 Cr · +10.3% YoY
Concord Biotech Bonus Issue
Concord Biotech's postal ballot approved a bonus issue and an authorised capital increase. No cash is paid and no ratio is stated.
Other management change announcements
All →Edelweiss Financial Services Management Change
Promoter director Venkatachalam Ramaswamy resigned as Non-Executive Director and Vice Chairman effective November 11, 2026. He also sought reclassification from promoter to public category, pending approvals.
Abans Financial Services Management Change
Abans Financial Services' Chief Executive Officer Chintan Mehta resigned with immediate effect. Mayank Mundhra was appointed Whole-Time Director from November 11, 2026, subject to shareholder approval.
Ortin Global Management Change
Ortin Global's auditor M/s. Mathesh & Ramana resigned effective 12 Nov 2026, citing other professional commitments. S. D. Mehta and Co. was appointed as replacement.
Tierra Agrotech Management Change
Tierra Agrotech appointed Sridevi Dasari as Executive Director for 60 months, effective 16 November 2026. She is Group Company Secretary and Legal Head of CCL Products (India).
- Execution
- 60 months
National Peroxide Management Change
National Peroxide Limited appointed Mr. Amit Shah as General Manager – Sales & Marketing, effective 11 November 2026, as a senior management personnel change. The appointment was approved at a board meeting held the same day.
Naperol Investments Management Change
Naperol Investments appointed Mr. Vinay Divakar Jayade as Non-Executive Non-Independent Director and Ms. Jinal Shah as Company Secretary, both effective 11 November 2026. Board-approved appointments with no financial value disclosed.
- Execution
- 3 months (Mr. Jayade's term of appointment)